Aggressive natural killer leukemia (ANKL) is a proliferation of mature natural killer (NK) cells. It is very rare (fewer than 350 cases reported in the literature), with most cases described in young and middle-aged persons from China, Japan, and South America.
ANKL is almost always associated with Epstein-Barr virus (EBV) infection. Hemophagocytic lymphohistiocytosis (HLH) is reported in 60% of cases.
The main sites of involvement include the liver and spleen, the bone marrow and peripheral blood, and, less frequently, the nose and skin. Clinically, these patients commonly present with fever and liver dysfunction with a rapidly progressive course.
ANKL has high mortality (median length of survival is approximately 8 weeks).
Aggressive natural killer cell leukemia
Alerts and Notices
Important News & Links
Synopsis
Codes
ICD10CM:
C94.80 – Other specified leukemias not having achieved remission
SNOMEDCT:
721310007 – Aggressive natural killer-cell leukemia
C94.80 – Other specified leukemias not having achieved remission
SNOMEDCT:
721310007 – Aggressive natural killer-cell leukemia
Look For
Subscription Required
Diagnostic Pearls
Subscription Required
Differential Diagnosis & Pitfalls
To perform a comparison, select diagnoses from the classic differential
Subscription Required
Best Tests
Subscription Required
Management Pearls
Subscription Required
Therapy
Subscription Required
References
Subscription Required
Last Reviewed:11/04/2020
Last Updated:11/22/2020
Last Updated:11/22/2020
Aggressive natural killer cell leukemia